Natural Biogenex completes its maiden fund-raise of Rs 18.75 Cr
The proceeds from this fund-raise will be deployed in financing the project requirements of the API business
The proceeds from this fund-raise will be deployed in financing the project requirements of the API business
Acquisition expands Merck’s growing hematology portfolio
The newly built complex of RRIUM, which will be under CCRUM, the apex government organization for research in Unani Medicine
The company offers a wide portfolio of services including integrated doctor-led prescription e-commerce enablement, digital health record management, and smart clinics.
The company has reported total income of Rs. 44.37 crores during the period ended September 30, 2022
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress
Prime Minister Narendra Modi attended an event marking the 100th robotic-assisted surgical system installation at U. N. Mehta Institute of Cardiology, Ahmedabad.
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
The company is focussed on increasing the capacity utilizations while controlling costs
The company sees the business reaching $100mn
Nikon’s newly launched product AXR Point scanning confocal microscope provides “World’s largest Field of View” of 25mm in one single shot
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022
The company has reported total income of Rs. 114.77 crores during the period ended September 30, 2022.
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
Subscribe To Our Newsletter & Stay Updated